Notice2022-09156
Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Engineered Influenza Neuraminidase Antigens
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 28, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive, sublicensable patent license to the University of Washington, located in Seattle, State of Washington, U.S.A. in its rights to the inventions and the patent applications listed in the Supplementary Information section of this notice.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 82 (Thursday, April 28, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 82 (Thursday, April 28, 2022)]
[Notices]
[Pages 25285-25286]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-09156]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License, Inter-Institutional
Agreement-Institution Lead: Engineered Influenza Neuraminidase Antigens
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases
(NIAID), an institute of the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is contemplating the
grant of an exclusive, sublicensable patent license to the University
of Washington, located in Seattle, State of Washington, U.S.A. in its
rights to the inventions and the patent applications listed in the
Supplementary Information section of this notice.
DATES: Only written comments and/or applications for a license which
are
[[Page 25286]]
received by the Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases (NIAID) on or
before May 13, 2022 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Amy Petrik, Technology Transfer and Patent
Specialist, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases, 5601 Fishers
Lane, Suite 6D, MSC9804, Rockville, MD 20852-9804, phone number 240-
627-3721, or <a href="/cdn-cgi/l/email-protection#e8898591c6988d9c9a8183a8868180c68f879e"><span class="__cf_email__" data-cfemail="7514180c5b051001071c1e351b1c1d5b121a03">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The following and all continuing patents/
patent applications thereof are the intellectual property to be
licensed under the prospective agreement to the University of
Washington: United States Provisional Patent Application Number 62/
986,295, filed March 6, 2020, entitled ``Engineered Influenza
Neuraminidase Antigens'' (HHS Reference No. E-052-2021-0-US-01) and
Patent Cooperation Treaty (PCT) Patent Application Number PCT/US2021/
020804, filed March 4, 2021, entitled ``Engineered Influenza
Neuraminidase Antigens'' (HHS Reference No. E-052-2021-0-PCT-02).
The patent rights in these inventions have been assigned to the
University of Washington and Government of the United States of America
as represented by the Secretary, Department of Health & Human Services.
The prospective patent license will be for the purpose of
consolidating the patent rights to the University of Washington, the
co-owners of said rights, for commercial development and marketing.
Consolidation of these co-owned rights is intended to expedite
development of the invention, consistent with the goals of the Bayh-
Dole Act codified as 35 U.S.C. 200-212.
The prospective inter-institutional agreement may include an
exclusive license for NIAID's rights in these jointly owned patent
applications. It will be sublicensable, and any sublicenses granted by
the University of Washington will be subject to the provisions of 37
CFR part 401 and 404.
In the subject technology, researchers at NIAID and the University
of Washington engineered the neuraminidase glycoprotein from the
influenza virus to improve its properties as an antigen. The patent
applications claim the mutations that the researchers introduced to
stabilize the neuraminidase protein in its closed conformation and use
of the engineered protein in an influenza vaccine.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will include a share of the
royalties from the licensing of this invention back to the NIAID, and
may be granted unless within fifteen (15) days from the date of this
published notice, NIAID receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
Complete license applications submitted in response to this Notice
will be presumed to contain business confidential information and any
release of information in these license applications will be made only
as required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: April 25, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-09156 Filed 4-27-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 28, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.